How a joined-up development strategy pays off for early-stage biotechs

Parexel Biotech’s Nate Akers and Vicky Hsu discuss how important it is for biotechs to align clinical execution with a clearly defined regulatory strategy to increase the chance of success for a new drug program.


Get Exclusive PDF Access

Return to Insights Center

Related Insights

Related Insights

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Blog

Master Protocol Trials: What Are the Elements of Success?

Dec 1, 2021

Webinar

Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development

May 6, 2025

Playbook

Streamlining development in the EU: Strategies for smoother CTA submissions

Feb 27, 2025

Show more